Founded in 2014 with $40m in the bank, Therachon AG is developing TA-46 for achondroplasia, a molecule that CEO Luca Santarelli said the company evolved from an "academic prototype," created by founder Elvire Gouze, into what Santarelli hopes will be a solid industrial program, ultimately meeting the high unmet need for those suffering from genetic dwarfism.
Achondroplasia is an autosomal dominant disorder caused by a single amino acid mutation in the fibroblast growth factor receptor 3...








